KaloBios tacks on $12M more for engineered antibodies
South San Francisco, Calif.-based KaloBios, a biotech company that raised $20 million just five months ago, has added another $12 million in a second close of its fourth round of venture capital.
KaloBios has three antibody products in development, each of which targets a specific set of diseases. Two of the candidates, KB001 and KB002, have made it to Phase 2 clinical testing.
The new funding was led by Baxter International, one of the world’s largest healthcare… Continue Reading